AnaptysBio, Inc

AnaptysBio is headquartered in San Diego, California and operates primarily from the United States. Its business is global in the sense that collaboration agreements and future commercialization can extend into foreign markets, but the company’s disclosed operating footprint is centered in the U.S. The Vanda agreement explicitly includes potential regulatory and commercial milestones in both the U.S. and EU, showing that future value creation depends on multi-region approvals. The company also notes that its facilities are in a seismically active and wildfire-prone region, which creates operational concentration risk.

The company faces the core biotechnology risk that its product candidates may fail in clinical development or be delayed, which would reduce the likelihood of future commercialization. Safety findings, weak efficacy, or unfavorable trial results could impair regulatory approval and market acceptance, especially because the company’s pipeline is still early stage. AnaptysBio also depends on collaborators such as GSK and Vanda to execute development and commercialization, so partner decisions and timelines can materially affect revenue. In addition, the company is exposed to operational concentration risk because its facilities are in San Diego, a region subject to earthquakes, wildfires, and power disruptions, and it relies on a geographically concentrated supply chain.